Autolus Therapeutics (AUTL) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Autolus Therapeutics

NasdaqGS•Healthcare•Biotechnology

$1.88-0.08(-0.04%)Market closed

Market Cap

$516.35M

P/S

4.4x

P/B

6.9x

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

How this company scores

AverageMetricSide Score: 50/100

Strongest: Growth (18/25); weakest: Profitability (7/25).

Profitability7/25

Growth18/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality10/25

Strengths

Growing revenueInterest easily coveredCash-backed earningsConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 4.4x5y range 3.6x – 84.9x

Currently below its 9-quarter median.

P/B · 6.9x5y range 1.1x – 10.0x

Currently above its 12-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $516.35M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $117.39M
Q. Revenue: $45.69M
TTM EBITDA: $-236.92M
TTM Op. Income: $-247.44M
Q. Op. Income: $-43.84M
TTM Net Income: $-280.16M
Q. Net Income: $-39.11M
EPS: $-0.15
Shares Out.: $266.16M

$117.39M in TTM revenue grew 292.2% YoY, reaching $45.69M last quarter. TTM EBITDA of $-236.92M and TTM operating income of $-247.44M show growth is flowing through to the bottom line. However, net income is negative at $280.16M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 55.2%
EBITDA Margin: -90.1%
Op. Margin: -95.9%
Net Margin: -85.6%

Op. margin of -95.9% is up 196.6% YoY — cost efficiency is improving. Net margin at -85.6% and gross margin of 55.2% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 3 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 4.4x
P/B Ratio: 6.9x

P/S of 4.4x and P/B of 6.9x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $493.23M
Cash: $171.41M
Long-Term Debt: N/A
Book Value: $74.84M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-25.07M
TTM Free Cash Flow: $-232.73M
FCF Margin: -198.3%
FCF / Net Income: 0.8

TTM FCF of $-232.73M on $-25.07M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.